Literature DB >> 11709476

Imaging appearances of metastases from neuroendocrine tumours of the pancreas.

M P Debray1, O Geoffroy, J P Laissy, R Lebtahi, O Silbermann-Hoffman, M C Henry-Feugeas, G Cadiot, M Mignon, E Schouman-Claeys.   

Abstract

Endocrine tumours of the pancreas (ETPs) are rare neoplasms that are frequently malignant. Despite their usual slow growth, metastases do occur and have a major impact on prognosis. Metastases may be the first manifestation of disease, and recognition of particular radiological features of these hypervascular metastases should suggest their possible neuroendocrine origin. Although somatostatin receptor scintigraphy has changed the imaging strategy for these tumours and has become their principal imaging modality, radiological techniques are still required for precise localization of scintigraphic hot spots and monitoring of response to therapy. This pictorial review shows the typical radiological features of ETP metastases and emphasizes the role of different imaging modalities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709476     DOI: 10.1259/bjr.74.887.741065

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  16 in total

1.  Imaging of gastroenteropancreatic neuroendocrine tumors.

Authors:  Eik Hock Tan; Cher Heng Tan
Journal:  World J Clin Oncol       Date:  2011-01-10

2.  Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI.

Authors:  Giovanni Foti; Letizia Boninsegna; Massimo Falconi; Roberto Pozzi Mucelli
Journal:  Radiol Med       Date:  2013-07-25       Impact factor: 3.469

3.  Pancreatic and peripancreatic somatostatinomas.

Authors:  J M L Williamson; C C Thorn; D Spalding; R C N Williamson
Journal:  Ann R Coll Surg Engl       Date:  2011-07       Impact factor: 1.891

4.  Non-functioning gastroenteropancreatic (GEP) tumors: a 111In-Pentetreotide SPECT/CT diagnostic study.

Authors:  Angela Spanu; Orazio Schillaci; Bastiana Piras; Diego F Calvisi; Antonio Falchi; Roberta Danieli; Susanna Nuvoli; Franca Dore; Giuseppe Madeddu
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

5.  Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

Authors:  Matthew H Kulke; Lillian L Siu; Joel E Tepper; George Fisher; Deborah Jaffe; Daniel G Haller; Lee M Ellis; Jacqueline K Benedetti; Emily K Bergsland; Timothy J Hobday; Eric Van Cutsem; James Pingpank; Kjell Oberg; Steven J Cohen; Mitchell C Posner; James C Yao
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

6.  Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours.

Authors:  Nils F Schreiter; Munenobu Nogami; Ingo Steffen; Ulrich-Frank Pape; Bernd Hamm; Winfried Brenner; Rainer Röttgen
Journal:  Eur Radiol       Date:  2011-09-09       Impact factor: 5.315

Review 7.  Treatment of Zollinger-Ellison syndrome.

Authors:  Paola Tomassetti; Davide Campana; Lydia Piscitelli; Elena Mazzotta; Emilio Brocchi; Raffaele Pezzilli; Roberto Corinaldesi
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

8.  Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?

Authors:  H Amthauer; J Ruf; M Böhmig; E Lopez-Hänninen; T Rohlfing; K-D Wernecke; U Plöckinger; M Gutberlet; A-J Lemke; T Steinmüller; B Wiedenmann; R Felix
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-03       Impact factor: 9.236

9.  Insulinoma Causing Prolonged Hypoglycaemic Coma.

Authors:  Prabhat Kumar; Ajay Chauhan; Juhi Dixit; Harish Gupta
Journal:  J Clin Diagn Res       Date:  2016-08-01

10.  Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors.

Authors:  Jonas Apitzsch; Frederik Anton Verburg; Felix Mottaghy; Alexander Heinzel
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.